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Oxidative Imbalance in Children and Adolescents with 
Autism Spectrum Disorder 
Onder Ozturk1, Omer Basay1, Burge Kabukcu Basay1, Huseyin Alacam2, Ahmet Buber3,
Bunyamin Kaptanoglu4, Yasar Enli5, Mustafa Dogan6, Omer Faruk Tuncer3, Aysen Cetin Kardesler7
ABSTRACT:
Oxidative imbalance in children and adolescents with autism spectrum disorder 
Objective: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments 
in social interactions and behavioral problems. Various genetic and environmental factors, including 
oxidative stress, are claimed to play a role in the etiopathogenesis of ASD. In this study, we aimed to examine 
the status of oxidative metabolism in ASD and the association between oxidative parameters and ASD 
symptom severity and subtype of ASD. 
Method: Thirty-three children and adolescents diagnosed with ASD (16 children diagnosed with autistic 
disorder, 13 children with pervasive developmental disorder not otherwise specified, and 4 children with 
Asperger syndrome) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision (DSM-IV-TR) and 28 healthy controls, aged 2-17 years, were recruited in this study. Total 
oxidant status (TOS) and total antioxidant status (TAS) were evaluated using Rel Assay Kit in children and 
adolescents. The oxidative stress index (OSI) was calculated by dividing the TOS values by the TAS values. 
Autistic symptoms for these patients were scored on the Childhood Autism Rating Scale (CARS). 
Results: In patients with ASD, TAS was statistically significantly lower and OSI statistically significantly 
higher than in healthy controls. There were no statistically significant differences in TOS between the ASD 
and control groups. There were no statistically significant differences between the subtypes of ASD in terms 
of oxidative stress parameters. In addition, TAS, TOS, and OSI values did not differ statistically significantly 
between the patients’ CARS groups, and were not associated with the CARS scores of the patients. 
Conclusion: Our findings suggest that oxidative imbalance is present in ASD and that oxidative stress may 
play a role in the etiopathogenesis of ASD. Therefore, it is suggested that antioxidants may have beneficial 
effects on ASD and may be a new therapeutic target in treating ASD.
Keywords: autism spectrum disorder, total oxidant status, total antioxidant status, oxidative stress index, 
oxidative stress
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INTRODUCTION
Autism spectrum disorder (ASD) is a heterogeneous 
group of  neurodevelopmental  disorders 
characterized by problems related to social 
interaction and behavioral area1. The causes and 
pathophysiology of ASD are not understood 
completely. It is likely that multiple genetic and 
environmental factors contribute to its etiology2. 
In recent years, the number of biological studies of 
ASD have increased in an attempt to determine the 
role of environmental factors in the etiology and 
pathophysiology of ASD3. Studies have suggested a 
pathophysiological role for oxidative stress, which 
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may be a crucial environmental factor in various 
psychiatric disorders, including anxiety disorders4, 
obsessive compulsive disorder (OCD)5, panic 
disorder6, attention deficit hyperactivity disorder 
(ADHD) 7,  bipolar  disorder  (BPD) 8,  and 
schizophrenia9. Oxidative damage may play a 
central role in the pathogenesis of ASD, just as it 
does in these other neuropsychiatric disorders10. 
Previous studies have reported increased oxidant 
stress, including nitric oxide, in ASD patients10-12. 
Normally, antioxidant defense mechanisms 
balance the activity of free radicals (FRs), creating 
homeostasis between oxidants and antioxidative 
systems. Oxidative stress is characterized by the 
production of excessive amounts of FRs, decreased 
levels of antioxidants, or both. In certain 
neuropsychiatric disorders this homeostasis is 
disrupted, and enhanced concentrations of FRs 
which can lead to neuronal damage in genetically 
predisposed persons13. The number of various 
antioxidants and FRs makes it difficult to measure 
them separately. Understanding the levels of total 
oxidative and antioxidative metabolism in patients 
with ASD may help clarify the biochemical 
mechanisms underlying these disorders. The 
process for measuring total antioxidative status 
(TAS) and total oxidative status (TOS) uses novel 
methods developed by Erel14,15. TAS test reflects a 
patient’s total antioxidant status, TOS test reflects 
total oxidant status, and the oxidative stress index 
(OSI) reveals current oxidative balance. 
 The present study aimed to examine oxidative 
metabolism in patients with ASD by measuring TOS, 
TAS and OSI values to determine changes in oxidative 
stress parameters that may contribute to the 
etiopathogenesis of ASD. In addition, we examined 
the association between these oxidative parameters 
and symptom severity and subtype of ASD. 
METHODS 
Participants and procedures
The study recruited 33 children and adolescents 
from 2-17 during routine visits between January 
and July 2015, diagnosed with ASD at the 
Pamukkale University School of Medicine, 
Department of Child and Adolescent Psychiatry. 
Patients were examined using a two-stage 
evaluation. In the first stage, they were diagnosed 
with ASD including autistic disorder (AD), 
Pervasive Developmental Disorder-Not Otherwise 
Specified (PDD-NOS), and Asperger syndrome 
(AS) according to Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) criteria by the senior child 
psychiatrist. In the second stage, autistic symptoms 
of these patients were evaluated with the 
Childhood Autism Rating Scale (CARS)16,17. Finally, 
the study enrolled 16 children diagnosed with AD, 
13 children with PDD-NOS, and 4 children with AS. 
Based on hospital staff and those attending the 
pediatric outpatient clinic for routine check-ups 
and various other reasons, the study recruited 28 
healthy controls from 2-17, matched for age and 
gender. The study excluded children with a history 
of psychiatric treatment in the control group. In 
addition, healthy controls had no family history of 
ASD. The study also excluded patients and healthy 
controls with an active infectious disease the 
previous week, who received any antioxidant 
agents, such as vitamin C or vitamin E, or who had 
a history of smoking or alcohol use. 
 All participants were informed about the nature 
of the study and signed an informed consent form 
in accordance with the Declaration of Helsinki. 
The local Ethics Committee of Pamukkale 
University School of Medicine approved the study.
Blood Samples and Measurement Tools
Venous blood samples were obtained from an 
antecubital vein after a 12-h overnight fasting 
period; 10 mL of venous blood from each 
participant was collected in biochemistry tubes. 
Samples were centrifuged at 5000 rpm for three 
min and serum obtained from the blood samples 
were frozen and stored at -20oC prior to analysis. 
After all samples were collected, biochemical 
analyses were made in the Biochemistry 
Laboratory of the Pamukkale University School of 
Medicine. 
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Measuring TOS 
The samples were first brought to room 
temperature (18-26 °C). Serum TOS was measured 
using a Rel Assay Kit. In this method, oxidants 
present in the sample oxidize the ferrous ion–
chelator complex to ferric ion. The presence of 
ferric ion leads to a change in color that can be 
measured spectrophotometrically, whereby the 
color intensity reflects the total amount of oxidant 
molecules present in the sample14.
Measuring TAS 
Before analyses, the serum was brought to room 
temperature (18-26°C) and the serum TAS was 
measured using a Rel Assay Kit. In this method, the 
hydroxyl radical reacts with the colorless substrate 
O-dianisidine to produce the dianisyl radical, 
which is bright yellowish-brown. Upon addition of 
a serum sample, the oxidative reactions initiated 
by the hydroxyl radicals present in the reaction 
mix are suppressed by the antioxidant components 
of the serum, preventing color change. This 
reaction is measured spectrophotometrically in 
automatic analysers to obtain the TAS value. 
Results are expressed as mmol Trolox Eqv./L15.
Calculating OSI 
The OSI was obtained by dividing the TOS by the 
TAS. The TAS mmol unit value was first translated 
to micromol units (i.e., the units used in the TOS 
test), then the OSI was calculated according to the 
following formula: OSI (arbitrary unit)=[TOS (μmol 
H2O2 Equiv./L)/TAS (mmol Trolox Equiv./L)] x 100.
Statistical Analysis
SPSS for Windows (version 17.0) was used for 
statistical analysis. Categorical variables were 
analyzed using the Chi-square test.  The 
distributions of the variables were assessed by the 
Shapiro–Wilk W test, and non-parametric tests 
were used for variables with non-normal 
distributions. The Mann-Whitney U test was used 
for continuous variables with two categories, and 
the Kruskal-Wallis tests were used for continuous 
variables with three categories. Spearman’s 
correlation analysis was performed to evaluate 
correlations between age, CARS scores, and TAS, 
TOS, and OSI levels. Statistical significance was 
defined as p<0.05.
RESULTS 
The study included 33 patients with ASD (25 males 
and 8 females) and 28 healthy controls (15 males 
and 13 females). The mean age of the ASD group 
was 8.72±3.73 years, and the mean age of the 
control group was 10.71±4.35 years. There were no 
statistically significant differences in mean age 
(p=0.60) or gender (p=0.69) distribution between 
the groups. Sociodemographic and clinical 
characteristics of the participants are shown in 
Table 1.
 The mean TAS values were statistically 
significantly lower and OSI values statistically 
significantly higher in the ASD group than in the 
control group (p<0.001). There were no statistically 
significant differences in TOS between the groups 
(p =0.297; Table 2).
 We found no statistically significant correlations 
Table 1: Demographic characteristic of patients with ASD and HC
ASD
(n=33)
HC
(n=28)
p
Age (mean years±SD) 8.72±3.73 10.71±4.35 0.060*
Sex (male/female) 25/8 15/13 0.069†
ASD subtypes (n,%)
Autism 16 (48.5)
PDD-NOS 13 (39.4)
Asperger disorder 4 (12.1)
*Independent-Samples T-Test, †Chi-squared test. ASD: Autism Spectrum Disorders, PDD-NOS Pervasive developmental disorder not otherwise specified, HC: healthy control, 
SD: standard deviation
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between CARS scores and TAS (r=-0.072, p=0.69), 
TOS (r=-0.020, p=0.91), and OSI (r=0.097, p=0.59) 
values for the patients. Patients were divided into 
three groups according to the CARS scores as 
follows: non-autistic group (patients with CARS 
scores between 15-29.5 points), mild to moderate 
autism group (patients with CARS scores between 
30-36.5 points) and severe autism group (patients 
with CARS scores greater than 36.5 points). The 
oxidative parameters including TAS, TOS and OSİ 
values were not statistically significantly different 
between the patients’ CARS groups. In addition, 
there were no statistically significant differences 
between the subtypes of ASD in terms of oxidative 
stress parameters (Table 3). 
DISCUSSION 
To our knowledge, this is the first study to examine 
TAS, TOS and OSI parameters in children with 
ASD. We demonstrated the presence of lower TAS 
and higher OSI levels in children with ASD.
 The antioxidant system consists of enzymatic 
and non-enzymatic components10. In general, it 
has been suggested that ASD patients have a 
weakened antioxidant system. Previous studies 
have reported lower glutathione peroxidase 
activity in ASD patients than in controls when 
measured in erythrocytes10 and in erythrocytes and 
plasma18. Similarly, lower erythrocyte superoxide 
dismutase activities were reported in autistic 
children than in healthy controls18. In addition, 
due to decreased nicotinamide adenine 
dinucleotide phosphate (i.e., the cofactor for 
g l u t a t h i o n e  r e d u c t a s e ) ,  l o w e r  p l a s m a 
concentrations of glutathione (GSH) and higher 
plasma concentrations of glutathione disulfide 
(GSSG) were reported in ASD children10,19. Vitamin 
E levels were reported to be consistently lower in 
ASD children than in heathy controls10. Parellada 
et al. (2012)20 demonstrated that the TAS of patients 
with AS was lower than those of the healthy 
controls and patients with psychosis at first 
episode. Our finding of decreased TAS in patients 
Table 2: Comparison of the oxidative stress parameters among groups
ASD
(n=33)
HC
(n=28)
p
TAS 0.42 (0.28-0.51) 0.76 (0.47-0.87) <0.001*
TOS 44.93 (43.56-48.56) 47.53 (43.69-49.52) 0.297
OSI 10.74 (8.64-16.80) 6.20 (5.19-9.80) <0.001*
Variables were expressed as median (25th–75th percentile). *Mann Whitney-U test, statistically significant p<0.05, ASD: Autism Spectrum Disorders, HC: healthy control,
TAS: total antioxidant status, TOS: total oxidant status, OSI: oxidative stress index 
Table 3: Comparison of the oxidative stress parameters among ASD subgroups and CARS groups
ASD subgroups
Autism
(n=16)
PDD-NOS
(n=13)
AS
(n=4)
p*
TAS 0.31 (0.18-0.45) 0.49 (0.35-0.61) 0.47 (0.40-0.53) 0.09
TOS 44.11 (43.15-45-58) 45.89 (44.11-49.31) 44.31 (42.46-48-42) 0.22
OSI 15.03 (9.74-25.06) 10.07 (7.25-14.11) 10.08 (8.23-10.86) 0.14
CARS groups
Non-autistic
group
(n=5)
Mild to moderate
autism group
(n=14)
Severe 
autism group
(n=14)
P*
TAS 0.52(0.41-0.70) 0.36 (0.27-0.49) 0.41 (0.24-0.53) 0.79
TOS 44.93(42.87-48.21) 44.93 (43.15-49.17) 44.79 (43.62-46.36) 0.91
OSI 9.52(6.61-10.79) 12.68 (9.41-17.33) 11.98 (8.25-20.03) 0.35
Variables were expressed as median (25th–75th percentile). *Kruskal-Wallis test, statistically significant p<0.05, ASD: Autism Spectrum Disorders,
PDD-NOS: Pervasive developmental disorder not otherwise specified, AS: Asperger syndrome, TAS: total antioxidant status, TOS: total oxidant status, OSI: oxidative stress index
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with ASD supported these previous results. 
Decreased TAS may increase neuronal damage 
caused by normal or enhanced oxidants impairing 
the defense mechanisms of vulnerable individuals. 
Post-mortem studies seem to support this view. A 
post-mortem study reported that the GSH/GSSG 
ratio, an indicator of antioxidant capacity, was 
lower in autism patients than in healthy controls, 
and the ratio was inversely correlated with 8-oxo-
deoxyguanosine (8-oxo-dG), which is a biomarker 
of oxidative deoxyribonucleic acid (DNA) 
damage21. Therefore, the results of the present 
study suggest that decreased antioxidant capacity 
in ASD children may play a crucial role in ASD 
pathogenesis.
 Oxidants may be produced by physiological or 
pathological processes22. Most studies have 
demonstrated increases in various oxidant markers 
in ASD children. In particular, elevated nitric oxide 
(NO) levels were consistently reported among ASD 
patients in various studies,11,23,24 as were elevated 
thiobarbituric acid reactive substances and 
xanthine oxidase activity in red blood cells25 and 
increased levels of 8-isoprostane (8-iso-PGF2a), a 
lipid peroxidation biomarker26 in autism. Increases 
in these substances indicate excess oxidants in 
autistic patients compared to controls. An elevated 
concentration of oxidants in cells may lead to cell 
damage and death22,27. Studies investigating the 
reason for the elevated oxidants found evidence 
for mitochondrial dysfunction in patients with 
ASD28,29. Because of the electron transport system 
(ETS), mitochondria is the predominant source of 
oxidants and the major target of FRs30,31. 
Mitochondrial dysfunction may cause increased 
reactive oxygen species and oxidative damage32.
 Interestingly, in contrast with TAS, the present 
study found no significant differences in TOS 
values between ASD children and the control 
group. This result seems to contradict those of 
previous studies. However, in previous studies, 
oxidant parameters were evaluated separately, 
which is a fairly difficult and expensive method. 
The present study was the first to measure the 
cumulative oxidant effects of these agents. In 
addition, TOS and TAS may not always show strong 
negative correlations in individuals. Therefore, 
measuring the OSI parameters provides better 
information about patients’ oxidative stress.
 The present study demonstrated an increase in 
OSI values in patients with ASD. An oxidative 
imbalance between oxidants and antioxidant 
systems has been reported in neuropsychiatric 
disorders, including ADHD33, OCD34, BPD8, and 
schizophrenia9. However, this study was the first 
time that OSI parameters were evaluated in ASD 
patients.
 The human brain is very sensitive to oxidative 
stress35. The brain utilizes 20% of the oxygen taken 
up by the body, even though it constitutes 
approximately 2% of body weight35,36. The expected 
result is that large amounts FRs, which are toxic to 
neurons, are produced in the brain. Large amounts 
of polyunsaturated fatty acids, which are oxidized 
easily, can increase the vulnerability of brain to 
FRs. In addition, a relatively weak antioxidant 
system in the brain contributes to damage to 
neuronal cells37. Therefore, increased oxidative 
stress may contribute to the pathogenesis of 
neuropsychiatric disorders like ASD that are 
caused by brain damage.
 Oxidative damage is caused by an increase in 
lipid peroxidation38, which leads to a loss of 
mitochondrial  membrane potential  and 
destruction of ETS activity39. Kern and Jones (2009) 
hypothesized that increased brain volume and loss 
of Purkinje cells are associated with lipid 
peroxidation in autism40. Post-mortem studies, 
conducted in patients with autism, have reported 
increased lipofuscin containing cells, which is a 
marker of oxidative stress in the brain41, and 
increased levels of 3-nitrotyrosine, which is an 
indicator of protein oxidation in the cerebellum42.
 It is thought that oxidative stress can cause 
DNA and RNA damage in patients with autism. A 
previous study showed an association between 
elevated oxidative stress and DNA damage in 
patients with BPD43. A post-mortem study reported 
significant increases in 8-oxo-dG in patients with 
autism21. James et al. (2004) reported that 
decreased methylation capacity may be associated 
with increased oxidative stress and impaired 
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transfer of methionine from S-adenosylmethionine 
to DNA, RNA, proteins, phospholipids, and 
neurotransmitters in children with autism44. In 
addition, studies investigating the effects of FRs on 
the brain have reported that they impair neuronal 
cell migration by promoting mutations in genes 
important to brain development45,46.
 In previous studies mitochondrial dysfunction, 
which causes oxidative imbalance32, was reported 
in ASD28,29. The oxidative imbalance may initiate 
mitochondrial and non-mitochondrial dependent 
cascades, which results in apoptosis37. Oxidative 
stress can lead to mast cell activation that 
promotes the secretion of various proinflammatory 
and neuro-sensitizing molecules, including 
bradykinin, histamine, IL-6, and NO47. These 
molecules may damage the gut-blood-brain 
barrier. Theoharides et al. (2009) speculated that 
permitting entero-toxic molecules to enter the 
brain may trigger neuro-inflammation in patients 
with autism48.
 Taken together, these findings suggest that 
oxidative stress may lead to neuronal damage and 
may contribute the pathogenesis of ASD by 
causing lipid and protein peroxidation, DNA and 
RNA damage, and neuroinflammation. Therefore, 
our findings of increased OSI in patients with ASD 
were concomitant with those of previous studies. 
The other major finding of the present study is 
that there was no difference between the TAS, 
TOS, and OSI values and ASD subtypes and 
disease severity (using CARS scores). These results 
cannot be compared with those of previous 
studies, because no other study has compared 
oxidative stress parameters in ASD subtypes. This 
finding may indicate that oxidative imbalance in 
ASD children is independent of subtypes and 
symptom severity.
 The most prominent limitation of the present 
study is its relatively small sample size. The other 
limitation is the cross-sectional design of our 
study. Although there is no statistically significant 
difference in the gender distribution between the 
patient and control groups, another limitation is 
disproportion in the distribution of girls and boys 
in the ASD and control groups, which is in turn 
related to the small sample size. Finally, we 
evaluated a wide range of ages. Therefore, these 
results may be affected by possible variations in 
the effects of age on oxidative parameters. To our 
knowledge, this is the first study to examine TOS, 
TAS, OSI, and overall oxidative balance in children 
and adolescents with ASD. 
CONCLUSIONS
This study found decreased antioxidant capacity 
and impaired oxidative balance in children 
diagnosed with ASD. Given these findings, 
oxidative stress may play a crucial role in the 
pathogenesis of ASD, causing structural and 
functional neuronal damage in more than one 
pathway in vulnerable individuals. However, the 
effect seems to be independent of subtype and 
severity of ASD. Antioxidants may have beneficial 
effects on ASD and may be a new therapeutic 
target for treating ASD. Prospective studies with 
larger samples are needed to understand the exact 
effect of oxidative stress on ASD pathogenesis.
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